Susquehanna Fundamental Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-19,986	Closed	-$9.69M	–	1026
2025 Q1	$9.69M	Buy	19,986 +15,886	+387%	+$7.4M	0.14%	188
2024 Q4	$1.65M	Buy	+4,100	New	+$1.9M	0.02%	581
2024 Q2	$21M	Buy	+44,819	New	+$19.5M	0.48%	52
2023 Q3	–	Sell	-6,072	Closed	-$2.14M	–	597
2023 Q2	$2.14M	Hold	6,072	–	–	0.08%	236
2023 Q1	$1.91M	Sell	6,072 -5,530	-48%	-$1.66M	0.04%	382
2022 Q4	$3.35M	Sell	11,602 -16,411	-59%	-$5M	0.06%	366
2022 Q3	$8.11M	Buy	+28,013	New	+$8.06M	0.14%	212
2021 Q2	–	Sell	-10,768	Closed	-$2.31M	–	1790
2021 Q1	$2.31M	Sell	10,768 -26,862	-71%	-$5.9M	0.04%	589
2020 Q4	$8.89M	Buy	+37,630	New	+$8.63M	0.16%	168

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Susquehanna Fundamental Investments's VRTX Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 19,986 shares — an estimated $9.69M sold.

Susquehanna Fundamental Investments first reported a position in VRTX in Q4 2020 and held it in 9 quarters. The position peaked at $21M in Q2 2024. 1,560 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 19,986 Vertex Pharmaceuticals shares in Q2 2025, an estimated $9.69M.
Susquehanna Fundamental Investments first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Susquehanna Fundamental Investments's Vertex Pharmaceuticals position peaked at $21M in Q2 2024.
1,560 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.